[go: up one dir, main page]

NO20090057L - Regulatoriske nukleinsyre elementer - Google Patents

Regulatoriske nukleinsyre elementer

Info

Publication number
NO20090057L
NO20090057L NO20090057A NO20090057A NO20090057L NO 20090057 L NO20090057 L NO 20090057L NO 20090057 A NO20090057 A NO 20090057A NO 20090057 A NO20090057 A NO 20090057A NO 20090057 L NO20090057 L NO 20090057L
Authority
NO
Norway
Prior art keywords
elements
expression
sequence
gene
well
Prior art date
Application number
NO20090057A
Other languages
English (en)
Norwegian (no)
Inventor
Barbara Enenkel
Kerstin Sauter
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20090057L publication Critical patent/NO20090057L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20090057A 2006-07-26 2009-01-06 Regulatoriske nukleinsyre elementer NO20090057L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117862 2006-07-26
PCT/EP2007/055954 WO2008012142A1 (de) 2006-07-26 2007-06-15 Regulatorische nukleinsäureelemente

Publications (1)

Publication Number Publication Date
NO20090057L true NO20090057L (no) 2009-02-16

Family

ID=37441548

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090057A NO20090057L (no) 2006-07-26 2009-01-06 Regulatoriske nukleinsyre elementer

Country Status (22)

Country Link
US (3) US20080124760A1 (sl)
EP (1) EP2049671B1 (sl)
JP (1) JP5270544B2 (sl)
KR (1) KR101485853B1 (sl)
CN (1) CN101517085B (sl)
AR (1) AR061472A1 (sl)
AU (1) AU2007278368B2 (sl)
BR (1) BRPI0714594A2 (sl)
CA (1) CA2658595C (sl)
CY (1) CY1113711T1 (sl)
DK (1) DK2049671T3 (sl)
EA (1) EA016880B1 (sl)
ES (1) ES2401654T3 (sl)
IL (1) IL196676A0 (sl)
MX (1) MX2009000781A (sl)
NO (1) NO20090057L (sl)
NZ (1) NZ575115A (sl)
PL (1) PL2049671T3 (sl)
PT (1) PT2049671E (sl)
SI (1) SI2049671T1 (sl)
TW (1) TW200815591A (sl)
WO (1) WO2008012142A1 (sl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
SG194473A1 (en) 2011-04-13 2013-12-30 Ca Nat Research Council EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNa2
CN107880123A (zh) 2011-10-28 2018-04-06 普罗典娜生物科学有限公司 识别α‑突触核蛋白的人源化抗体
RU2639519C2 (ru) * 2011-12-22 2017-12-21 Ф.Хоффманн-Ля Рош Аг Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
AU2013211874B2 (en) 2012-01-27 2017-11-02 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
JP2017512772A (ja) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Lg1〜3に特異的な抗ラミニン4抗体
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
SI3265563T1 (sl) 2015-02-02 2021-08-31 Meiragtx Uk Ii Limited Uravnavanje izražanja genov z modulacijo alternativnega združevanja, posredovano z aptamerjem
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗mcam抗体の使用
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
AU2017434556B2 (en) 2017-09-28 2024-11-14 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
CN111433223B (zh) 2017-11-29 2024-08-27 诺和诺德A/S(股份有限公司) 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
UA129124C2 (uk) 2018-11-08 2025-01-22 Протена Біосайєнсіс Лімітед Антитіла, що розпізнають тау
EP3817773B1 (en) 2018-11-26 2024-07-24 Forty Seven, Inc. Humanized antibodies against c-kit
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
KR20230026489A (ko) 2020-06-24 2023-02-24 프로테나 바이오사이언시즈 리미티드 소르틸린을 인지하는 항체
CA3217224A1 (en) * 2021-04-21 2022-10-27 Janssen Biotech, Inc. Materials and methods for improved phosphotransferases
AR133834A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Agentes de penetración célular y sus usos
TW202528337A (zh) 2023-09-15 2025-07-16 愛爾蘭商普羅希那平台科技有限公司 包括細胞穿透藥劑之方法、組合物、及套組
AR133828A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US5786166A (en) 1991-10-25 1998-07-28 University Of Tennessee Research Corporation Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
DE69730592T2 (de) 1996-01-11 2005-09-29 Immunex Corp., Thousand Oaks Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme
WO2000034526A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034326A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034325A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
AUPP967999A0 (en) * 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
JP2003504059A (ja) 1999-07-12 2003-02-04 ジェネンテック・インコーポレーテッド 発現ベクターと方法
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
WO2002081677A2 (en) 2001-04-05 2002-10-17 Ml Laboratories Plc Improved gene expression
ATE466941T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
DE10256083A1 (de) 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen

Also Published As

Publication number Publication date
DK2049671T3 (da) 2013-04-08
WO2008012142A1 (de) 2008-01-31
EP2049671A1 (de) 2009-04-22
KR101485853B1 (ko) 2015-01-23
SI2049671T1 (sl) 2013-04-30
PL2049671T3 (pl) 2013-05-31
CY1113711T1 (el) 2016-06-22
CN101517085B (zh) 2013-08-07
US20150337333A1 (en) 2015-11-26
CN101517085A (zh) 2009-08-26
PT2049671E (pt) 2013-01-24
HK1134107A1 (en) 2010-04-16
BRPI0714594A2 (pt) 2013-02-19
ES2401654T3 (es) 2013-04-23
US9708626B2 (en) 2017-07-18
US20100311121A1 (en) 2010-12-09
KR20090046887A (ko) 2009-05-11
EP2049671B1 (de) 2012-12-19
EA016880B1 (ru) 2012-08-30
EA200900212A1 (ru) 2009-10-30
CA2658595A1 (en) 2008-01-31
US9045776B2 (en) 2015-06-02
NZ575115A (en) 2011-10-28
CA2658595C (en) 2016-05-31
AU2007278368A1 (en) 2008-01-31
TW200815591A (en) 2008-04-01
US20080124760A1 (en) 2008-05-29
JP2009544293A (ja) 2009-12-17
MX2009000781A (es) 2009-01-29
IL196676A0 (en) 2011-08-01
AR061472A1 (es) 2008-08-27
AU2007278368B2 (en) 2013-12-19
JP5270544B2 (ja) 2013-08-21

Similar Documents

Publication Publication Date Title
NO20090057L (no) Regulatoriske nukleinsyre elementer
Perez et al. Influenza A virus-generated small RNAs regulate the switch from transcription to replication
Hoenen et al. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription
Ariga et al. NLR locus-mediated trade-off between abiotic and biotic stress adaptation in Arabidopsis
Bhattacharyya et al. Regulatory role of long non coding RNAs (lncRNAs) in neurological disorders: From novel biomarkers to promising therapeutic strategies
Yogendra et al. Metabolomics deciphers quantitative resistance mechanisms in diploid potato clones against late blight
García-Dorival et al. Elucidation of the cellular interactome of Ebola virus nucleoprotein and identification of therapeutic targets
Wang et al. Polymorphisms in cis‐elements confer SAUR26 gene expression difference for thermo‐response natural variation in Arabidopsis
MX2009003090A (es) Genes novedosos relacionados con ciclasa de glutaminilo.
Chen et al. The glutathione transferase of Nicotiana benthamiana Nb GSTU 4 plays a role in regulating the early replication of Bamboo mosaic virus
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
ATE473637T1 (de) Verwendung der crispr assoziierten gene (cas)
Gultyaev et al. Influenza virus RNA structure: unique and common features
PE20120115A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
Widjaja et al. Competition between influenza A virus genome segments
Kalyani et al. Post-transcriptional regulation of renalase gene by miR-29 and miR-146 MicroRNAs: implications for cardiometabolic disorders
Liu et al. Enhanced photosynthetic activity in pak choi hybrids is associated with increased grana thylakoids in chloroplasts
Balestrazzi et al. Genotoxic stress, DNA repair, and crop productivity
UA90098C2 (en) Promoter of vaccinia virus
WO2012097057A3 (en) Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
CY1118939T1 (el) Αντιδραστηρια εξαγωγης μεταλλου που διαθετουν αυξημενη ανθεκτικοτητα στην αποικοδομηση
AR065533A1 (es) Metodos de transcripcion, constructos de adn de repeticion en tandem, productores de proteinas que atacan geminivirus patogenos de plantas a traves de la interrupcion de los factores de transcripcion esenciales de los agentes patogenos
Duvall et al. Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen
EP2557173A3 (en) Cambium/Xylem-preferred promoters and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application